Nektar Therapeutics
$ 58.56
-8.30%
02 Jun - close price
- Market Cap 2,192,038,000 USD
- Current Price $ 58.56
- High / Low $ 63.00 / 57.83
- Stock P/E N/A
- Book Value 23.30
- EPS -7.93
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.54 %
- 52 Week High 109.00
- 52 Week Low 7.99
About
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Analyst Target Price
$153.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-04 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -1.82 | -1.2898 | -1.87 | -2.95 | -3.61 | -0.15 | -2.65 | -2.81 | -2.76 | -0.22 | -2.85 | -4.05 |
| Estimated EPS | -1.56 | -3.495 | -2.79 | -3.03 | -2.82 | -0.195 | -3.09 | -3.01 | -3.07 | -0.21 | -2.4 | -3.3 |
| Surprise | -0.26 | 2.2052 | 0.92 | 0.08 | -0.79 | 0.045 | 0.44 | 0.2 | 0.31 | -0.01 | -0.45 | -0.75 |
| Surprise Percentage | -16.6667% | 63.0959% | 32.9749% | 2.6403% | -28.0142% | 23.0769% | 14.2395% | 6.6445% | 10.0977% | -4.7619% | -18.75% | -22.7273% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -2.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTR
2026-05-28 04:08:49
Nektar Therapeutics announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled from June 2-4, 2026, in New York. Company management will webcast a fireside chat on June 3, 2026, at 1:20 p.m. Eastern Time. Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for autoimmune and chronic inflammatory diseases, with its lead product candidate, rezpegaldesleukin, currently in Phase 2b and Phase 2 clinical trials.
2026-05-27 22:39:33
Nektar Therapeutics announced its participation in the 2026 Jefferies Global Healthcare Conference, taking place in New York from June 2-4, 2026. Company management will webcast a fireside chat on June 3, 2026, at 1:20 p.m. Eastern Time. Nektar Therapeutics is a clinical-stage biotechnology company focused on treatments for autoimmune and chronic inflammatory diseases, with its lead candidate, rezpegaldesleukin, undergoing Phase 2b clinical trials.
2026-05-27 22:39:33
Nektar Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference in New York. The company’s management will host a fireside chat on Wednesday, June 3, 2026, at 1:20 p.m. ET, which will be webcast live and available for a 30-day replay. This event continues Nektar’s active communication strategy following recent financial and development updates.
2026-05-27 11:31:20
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Nektar Therapeutics (NASDAQ:NKTR) regarding potential corporate wrongdoing. The firm is encouraging investors who bought Nektar securities before February 26, 2025, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
2026-05-26 22:09:54
Nektar Therapeutics' Interim CFO, Linda M. Rubinstein, has filed an initial Form 3 statement of beneficial ownership. This filing reports her status as an officer, Interim CFO, but indicates no purchases, sales, or other transactions of Nektar Therapeutics securities. The Form 3 serves as an initial disclosure of her ownership rather than a trading event, clarifying that she is not a ten percent owner and has not engaged in derivative option exercises.
2026-05-25 11:39:40
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NASDAQ:NKTR) for corporate wrongdoing. The firm encourages stockholders who purchased Nektar securities before February 26, 2025, and still hold them, to connect and assist with the investigation, noting there is no cost to investors as the firm operates on a contingency fee basis.
